EGFR and head and neck squamous cell carcinoma: Van Keulen et al.’s study found that NIR fluorescently guided surgery using anti-EGFR antibodies conjugated to a NIR probe (panitumumab-IRDye800CW) helped improve surgeon decision making for 3/14 head and neck squamous cell carcinoma resections [51].